ES2861385T3 - Método para producir un gel que contiene un lisado de plaquetas - Google Patents

Método para producir un gel que contiene un lisado de plaquetas Download PDF

Info

Publication number: ES2861385T3
Authority: ES; Spain
Prior art keywords: lph; cells; gel; platelet lysate; lyophilized
Prior art date: 2016-06-02
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

ES16172608T

Other languages

English (en)

Spanish (es)

Inventor

Hatim Hemeda

Christian Wilkes

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

PL BioScience GmbH

Original Assignee

PL BioScience GmbH

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-06-02

Filing date

2016-06-02

Publication date

2021-10-06

2016-06-02 Application filed by PL BioScience GmbH filed Critical PL BioScience GmbH

2021-10-06 Application granted granted Critical

2021-10-06 Publication of ES2861385T3 publication Critical patent/ES2861385T3/es

Status Active legal-status Critical Current

2036-06-02 Anticipated expiration legal-status Critical

Links

239000006166 lysate Substances 0.000 title claims abstract description 60
238000000034 method Methods 0.000 title description 18
239000000463 material Substances 0.000 claims abstract description 48
239000000758 substrate Substances 0.000 claims abstract description 18
239000000126 substance Substances 0.000 claims abstract description 9
230000002401 inhibitory effect Effects 0.000 claims abstract description 7
238000012258 culturing Methods 0.000 claims abstract description 5
210000004027 cell Anatomy 0.000 claims description 65
210000002536 stromal cell Anatomy 0.000 claims description 12
239000000499 gel Substances 0.000 description 80
210000001772 blood platelet Anatomy 0.000 description 72
239000002609 medium Substances 0.000 description 23
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
238000001035 drying Methods 0.000 description 13
239000001963 growth medium Substances 0.000 description 13
230000035755 proliferation Effects 0.000 description 12
238000004113 cell culture Methods 0.000 description 11
238000004108 freeze drying Methods 0.000 description 10
239000000203 mixture Substances 0.000 description 10
238000005259 measurement Methods 0.000 description 9
239000012071 phase Substances 0.000 description 9
230000001464 adherent effect Effects 0.000 description 8
238000007710 freezing Methods 0.000 description 8
230000008014 freezing Effects 0.000 description 8
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 8
230000004069 differentiation Effects 0.000 description 7
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 7
239000002953 phosphate buffered saline Substances 0.000 description 7
IJRKANNOPXMZSG-SSPAHAAFSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC(=O)CC(O)(C(O)=O)CC(O)=O IJRKANNOPXMZSG-SSPAHAAFSA-N 0.000 description 6
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 6
230000004663 cell proliferation Effects 0.000 description 6
239000000306 component Substances 0.000 description 6
239000013078 crystal Substances 0.000 description 6
239000003102 growth factor Substances 0.000 description 6
229960002897 heparin Drugs 0.000 description 6
229920000669 heparin Polymers 0.000 description 6
239000007788 liquid Substances 0.000 description 6
239000000047 product Substances 0.000 description 6
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 5
238000004458 analytical method Methods 0.000 description 5
210000004369 blood Anatomy 0.000 description 5
239000008280 blood Substances 0.000 description 5
210000002950 fibroblast Anatomy 0.000 description 5
230000008569 process Effects 0.000 description 5
238000000859 sublimation Methods 0.000 description 5
230000008022 sublimation Effects 0.000 description 5
239000013589 supplement Substances 0.000 description 5
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
229930182816 L-glutamine Natural products 0.000 description 4
229930182555 Penicillin Natural products 0.000 description 4
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
238000003556 assay Methods 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
239000008103 glucose Substances 0.000 description 4
229940049954 penicillin Drugs 0.000 description 4
239000000243 solution Substances 0.000 description 4
238000010186 staining Methods 0.000 description 4
229960005322 streptomycin Drugs 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 3
241000283690 Bos taurus Species 0.000 description 3
108091003079 Bovine Serum Albumin Proteins 0.000 description 3
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
239000006143 cell culture medium Substances 0.000 description 3
230000010261 cell growth Effects 0.000 description 3
238000005345 coagulation Methods 0.000 description 3
230000015271 coagulation Effects 0.000 description 3
239000012894 fetal calf serum Substances 0.000 description 3
239000012634 fragment Substances 0.000 description 3
230000008105 immune reaction Effects 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
238000002955 isolation Methods 0.000 description 3
230000007774 longterm Effects 0.000 description 3
239000011159 matrix material Substances 0.000 description 3
244000052769 pathogen Species 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
210000000130 stem cell Anatomy 0.000 description 3
239000003634 thrombocyte concentrate Substances 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
NDVRKEKNSBMTAX-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;phosphoric acid Chemical compound OP(O)(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O NDVRKEKNSBMTAX-BTVCFUMJSA-N 0.000 description 2
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
238000012424 Freeze-thaw process Methods 0.000 description 2
WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
108090000190 Thrombin Proteins 0.000 description 2
206010052428 Wound Diseases 0.000 description 2
208000027418 Wounds and injury Diseases 0.000 description 2
230000009815 adipogenic differentiation Effects 0.000 description 2
210000000577 adipose tissue Anatomy 0.000 description 2
239000003146 anticoagulant agent Substances 0.000 description 2
229940127219 anticoagulant drug Drugs 0.000 description 2
238000002617 apheresis Methods 0.000 description 2
239000012298 atmosphere Substances 0.000 description 2
230000005540 biological transmission Effects 0.000 description 2
210000000988 bone and bone Anatomy 0.000 description 2
210000001185 bone marrow Anatomy 0.000 description 2
229960004494 calcium gluconate Drugs 0.000 description 2
239000004227 calcium gluconate Substances 0.000 description 2
235000013927 calcium gluconate Nutrition 0.000 description 2
NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
230000002648 chondrogenic effect Effects 0.000 description 2
230000030944 contact inhibition Effects 0.000 description 2
210000004748 cultured cell Anatomy 0.000 description 2
230000001186 cumulative effect Effects 0.000 description 2
238000003795 desorption Methods 0.000 description 2
238000010586 diagram Methods 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
229940079593 drug Drugs 0.000 description 2
230000000694 effects Effects 0.000 description 2
210000002391 femur head Anatomy 0.000 description 2
238000000684 flow cytometry Methods 0.000 description 2
238000011534 incubation Methods 0.000 description 2
230000001939 inductive effect Effects 0.000 description 2
238000012792 lyophilization process Methods 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
239000003068 molecular probe Substances 0.000 description 2
238000004264 monolayer culture Methods 0.000 description 2
210000005087 mononuclear cell Anatomy 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
229940012957 plasmin Drugs 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
230000002035 prolonged effect Effects 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
238000005496 tempering Methods 0.000 description 2
229960004072 thrombin Drugs 0.000 description 2
CHADEQDQBURGHL-UHFFFAOYSA-N (6'-acetyloxy-3-oxospiro[2-benzofuran-1,9'-xanthene]-3'-yl) acetate Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(OC(C)=O)C=C1OC1=CC(OC(=O)C)=CC=C21 CHADEQDQBURGHL-UHFFFAOYSA-N 0.000 description 1
XTPHKYNJCMSGJK-UHFFFAOYSA-N 2-(1H-tetrazol-1-ium-1-yl)-1,3-thiazole bromide Chemical compound S1C(=NC=C1)[NH+]1N=NN=C1.[Br-] XTPHKYNJCMSGJK-UHFFFAOYSA-N 0.000 description 1
OAVCWZUKQIEFGG-UHFFFAOYSA-O 2-(5-methyl-2H-tetrazol-1-ium-1-yl)-1,3-thiazole Chemical compound CC1=NN=N[NH+]1C1=NC=CS1 OAVCWZUKQIEFGG-UHFFFAOYSA-O 0.000 description 1
BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
206010002153 Anal fissure Diseases 0.000 description 1
208000016583 Anus disease Diseases 0.000 description 1
206010003694 Atrophy Diseases 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
102000019034 Chemokines Human genes 0.000 description 1
108010012236 Chemokines Proteins 0.000 description 1
206010053567 Coagulopathies Diseases 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
102000012422 Collagen Type I Human genes 0.000 description 1
108010022452 Collagen Type I Proteins 0.000 description 1
102000001187 Collagen Type III Human genes 0.000 description 1
108010069502 Collagen Type III Proteins 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
102000016359 Fibronectins Human genes 0.000 description 1
108010067306 Fibronectins Proteins 0.000 description 1
229920001917 Ficoll Polymers 0.000 description 1
208000009531 Fissure in Ano Diseases 0.000 description 1
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
206010020100 Hip fracture Diseases 0.000 description 1
101100075195 Homo sapiens LCT gene Proteins 0.000 description 1
101000797623 Homo sapiens Protein AMBP Proteins 0.000 description 1
101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
101000699781 Homo sapiens Retrotransposon Gag-like protein 4 Proteins 0.000 description 1
238000000134 MTT assay Methods 0.000 description 1
231100000002 MTT assay Toxicity 0.000 description 1
239000002033 PVDF binder Substances 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
102000029797 Prion Human genes 0.000 description 1
108091000054 Prion Proteins 0.000 description 1
102100032859 Protein AMBP Human genes 0.000 description 1
102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
102100029131 Retrotransposon Gag-like protein 4 Human genes 0.000 description 1
238000000692 Student's t-test Methods 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
241000700605 Viruses Species 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
230000001133 acceleration Effects 0.000 description 1
230000002293 adipogenic effect Effects 0.000 description 1
RGCKGOZRHPZPFP-UHFFFAOYSA-N alizarin Chemical compound C1=CC=C2C(=O)C3=C(O)C(O)=CC=C3C(=O)C2=C1 RGCKGOZRHPZPFP-UHFFFAOYSA-N 0.000 description 1
230000006907 apoptotic process Effects 0.000 description 1
230000037444 atrophy Effects 0.000 description 1
239000012620 biological material Substances 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000004271 bone marrow stromal cell Anatomy 0.000 description 1
229960005069 calcium Drugs 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
235000011089 carbon dioxide Nutrition 0.000 description 1
230000034303 cell budding Effects 0.000 description 1
230000024245 cell differentiation Effects 0.000 description 1
238000001516 cell proliferation assay Methods 0.000 description 1
238000002659 cell therapy Methods 0.000 description 1
230000008859 change Effects 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
230000009816 chondrogenic differentiation Effects 0.000 description 1
230000035602 clotting Effects 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
239000000512 collagen gel Substances 0.000 description 1
229940096422 collagen type i Drugs 0.000 description 1
230000001332 colony forming effect Effects 0.000 description 1
238000002316 cosmetic surgery Methods 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000000432 density-gradient centrifugation Methods 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
239000003814 drug Substances 0.000 description 1
230000002500 effect on skin Effects 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
238000002389 environmental scanning electron microscopy Methods 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
238000001914 filtration Methods 0.000 description 1
238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
239000010931 gold Substances 0.000 description 1
229910052737 gold Inorganic materials 0.000 description 1
239000001046 green dye Substances 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
230000011132 hemopoiesis Effects 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
239000011261 inert gas Substances 0.000 description 1
230000003993 interaction Effects 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
239000010410 layer Substances 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000007791 liquid phase Substances 0.000 description 1
238000011068 loading method Methods 0.000 description 1
239000008176 lyophilized powder Substances 0.000 description 1
239000012533 medium component Substances 0.000 description 1
239000013028 medium composition Substances 0.000 description 1
210000002901 mesenchymal stem cell Anatomy 0.000 description 1
VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
238000012758 nuclear staining Methods 0.000 description 1
238000010899 nucleation Methods 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
235000016709 nutrition Nutrition 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
230000009818 osteogenic differentiation Effects 0.000 description 1
230000002188 osteogenic effect Effects 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
229920002981 polyvinylidene fluoride Polymers 0.000 description 1
XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
235000019833 protease Nutrition 0.000 description 1
230000009467 reduction Effects 0.000 description 1
238000005057 refrigeration Methods 0.000 description 1
BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
238000011160 research Methods 0.000 description 1
239000000523 sample Substances 0.000 description 1
238000004626 scanning electron microscopy Methods 0.000 description 1
238000007789 sealing Methods 0.000 description 1
239000013049 sediment Substances 0.000 description 1
238000000926 separation method Methods 0.000 description 1
239000002356 single layer Substances 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
238000004544 sputter deposition Methods 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
238000003860 storage Methods 0.000 description 1
230000009897 systematic effect Effects 0.000 description 1
238000010257 thawing Methods 0.000 description 1
238000012546 transfer Methods 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
238000005406 washing Methods 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
230000029663 wound healing Effects 0.000 description 1
230000037303 wrinkles Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0062—General methods for three-dimensional culture
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0644—Platelets; Megakaryocytes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0656—Adult fibroblasts
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/70—Undefined extracts
- C12N2500/80—Undefined extracts from animals
- C12N2500/84—Undefined extracts from animals from mammals
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
- C12N2502/115—Platelets, megakaryocytes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2513/00—3D culture
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/50—Proteins
- C12N2533/56—Fibrin; Thrombin
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/90—Substrates of biological origin, e.g. extracellular matrix, decellularised tissue

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Wood Science & Technology (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Chemical & Material Sciences (AREA)
Microbiology (AREA)
Cell Biology (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Hematology (AREA)
Immunology (AREA)
Developmental Biology & Embryology (AREA)
Rheumatology (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Materials For Medical Uses (AREA)

ES16172608T 2016-06-02 2016-06-02 Método para producir un gel que contiene un lisado de plaquetas Active ES2861385T3 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP16172608.8A EP3252143B1 (en)	2016-06-02	2016-06-02	Method for producing a platelet-lysate-containing gel

Publications (1)

Publication Number	Publication Date
ES2861385T3 true ES2861385T3 (es)	2021-10-06

Family

ID=56148111

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ES16172608T Active ES2861385T3 (es)	2016-06-02	2016-06-02	Método para producir un gel que contiene un lisado de plaquetas

Country Status (8)

Country	Link
US (1)	US20200325442A1 (da)
EP (1)	EP3252143B1 (da)
JP (1)	JP2019517822A (da)
CN (2)	CN118147061A (da)
DK (1)	DK3252143T3 (da)
ES (1)	ES2861385T3 (da)
PT (1)	PT3252143T (da)
WO (1)	WO2017207688A1 (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20200078411A1 (en) *	2017-02-10	2020-03-12	Obatala Sciences, Inc.	Biological Scaffolds, Products Containing Biological Scaffolds and Methods of Using the Same
EP3633028A1 (en)	2018-10-02	2020-04-08	PL BioScience GmbH	Method for producing a virus-free platelet lysate material
CN110237094B (zh) *	2019-07-30	2023-10-03	天晴干细胞股份有限公司	一种底层血小板因子贴及sPL血小板因子凝胶贴膜的制备方法
WO2022050282A1 (ja) *	2020-09-01	2022-03-10	株式会社セルファイバ	足場、足場の製造方法、細胞培養物、細胞培養方法
CN115125191B (zh) *	2022-08-22	2023-10-13	浙江绿蔻生物技术有限公司	成纤维细胞转化培养基及其应用、成纤维细胞的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE8801537D0 (sv)	1988-04-26	1988-04-26	Ellco Food Ab	Cellodlingsmedium samt forfarande for dess framstellning
WO2008034803A1 (en)	2006-09-18	2008-03-27	Medizinische Universität Graz	Plasma-free platelet lysate for use as a supplement in cell cultures and for the preparation of cell therapeutics
EP2540819A1 (en)	2011-06-27	2013-01-02	Rheinisch-Westfälische Technische Hochschule Aachen (RWTH)	Method for cultivating cells in platelet-lysate-containing medium
TR201908716T4 (tr) *	2011-11-23	2019-07-22	Cell Therapy Ltd	Platelet lizat jeli.
US9682104B2 (en) *	2012-01-26	2017-06-20	Jadi Cell Llc	Lyophilized platelet lysates
KR102925966B1 (ko) *	2015-05-29	2026-02-10	자디 셀 엘엘씨	미립자 동결건조된 혈소판 용해물 조성물

2016
- 2016-06-01 US US16/305,910 patent/US20200325442A1/en active Pending
- 2016-06-02 DK DK16172608.8T patent/DK3252143T3/da active
- 2016-06-02 PT PT161726088T patent/PT3252143T/pt unknown
- 2016-06-02 ES ES16172608T patent/ES2861385T3/es active Active
- 2016-06-02 EP EP16172608.8A patent/EP3252143B1/en active Active
2017
- 2017-06-01 CN CN202410401108.5A patent/CN118147061A/zh active Pending
- 2017-06-01 CN CN201780046823.XA patent/CN109477068A/zh active Pending
- 2017-06-01 WO PCT/EP2017/063301 patent/WO2017207688A1/en not_active Ceased
- 2017-06-01 JP JP2019516068A patent/JP2019517822A/ja active Pending

Also Published As

Publication number	Publication date
WO2017207688A1 (en)	2017-12-07
JP2019517822A (ja)	2019-06-27
US20200325442A1 (en)	2020-10-15
EP3252143B1 (en)	2021-01-06
CN109477068A (zh)	2019-03-15
DK3252143T3 (da)	2021-03-22
EP3252143A1 (en)	2017-12-06
CN118147061A (zh)	2024-06-07
PT3252143T (pt)	2021-03-25

Publication	Publication Date	Title
ES2861385T3 (es)	2021-10-06	Método para producir un gel que contiene un lisado de plaquetas
ES2948810T3 (es)	2023-09-19	Método para obtener una población enriquecida de células madre mesenquimales funcionales, células así obtenidas y composiciones que las comprenden
S Choudhery et al.	2013	Utility of cryopreserved umbilical cord tissue for regenerative medicine
KR101321144B1 (ko)	2013-10-23	줄기세포 초자화 동결보존액 및 이를 이용하는 줄기세포 초자화 동결보존방법
Rendal-Vázquez et al.	2001	Effect of cryopreservation on human articular chondrocyte viability, proliferation, and collagen expression
KR20120078094A (ko)	2012-07-10	양수 줄기세포의 저온보존을 위한 동결배지 조성물 및 양수 줄기세포의 저온보존 방법
CN106359368A (zh)	2017-02-01	细胞冻存液及冻存方法
CN106465710A (zh)	2017-03-01	脂肪组织冻存液及脂肪组织冻存方法
ES2580377T3 (es)	2016-08-23	Método para cultivar células en un medio que contiene lisado de plaquetas
KR20020086678A (ko)	2002-11-18	조직 등가물의 동결 보존 방법 및 동결 보존된 조직 등가물
JP7105487B2 (ja)	2022-07-25	凍結移植体及び凍結移植体の製造方法
HK40111453A (zh)	2025-01-03	生产含有血小板裂解物的凝胶的方法
US20250197814A1 (en)	2025-06-19	Method for preserving cells
Enes et al.	2019	Clinical Application of Stem/Stromal Cells in COPD
CN114480285A (zh)	2022-05-13	一种胶质瘤类器官复苏液、培养液及复苏培养方法
UA155352U (uk)	2024-02-21	Спосіб одержання комплексного біотехнологічного продукту, що містить позаклітинні везикули від трьох типів клітин-продуцентів, для відновлення дефектів м'яких тканин
KR20130109078A (ko)	2013-10-07	양수 줄기세포의 냉동보존을 위한 동결배지 조성물 및 양수 줄기세포의 냉동보존 방법